H1 covers the moves that fit inside one budget cycle: rebalance design against validation, map where your evidence comes from, and reprice your US exposure. H2 and H3 cover the capabilities and structural shifts that decide whether those moves compound or get undone by the next policy turn.
Every quarter you wait, your 2027 trials get locked into sites and prices chosen under the old rules